Summary of Clinical Use

In the USA drotrecogin was FDA approved for the reduction of mortality in adult patients with severe sepsis, but was withdrawn (2011) due to a failure to show a survival benefit for patients with severe sepsis and septic shock

Mechanism Of Action and Pharmacodynamic Effects

Endogenous activated protein C exerts its antithrombotic effect by inhibiting blood coagulation factors Va and VIIIa. Drotrecogin alfa (activated) acts in the same way to produce its anti-thrombotic, anti-inflammatory, and profibrinolytic properties.